checkAd

TME Pharma Announces the Resignation of Its Chief Financial Officer Bryan Jennings

Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company's Chief Financial Officer (CFO), Bryan Jennings, has resigned for personal reasons. He will remain in his role through December 31, 2022, in order to ensure a smooth transition period.

To preserve financial resources, ongoing financing and partnering activities will be pursued by CEO Aram Mangasarian, long-standing members of staff Senior Vice President of Finance, Heike Balzer, and Vice President Legal and General Counsel, Karen Ophoff, as well as newly appointed Senior Director Investor Relations and Business Development, Ewelina Staniuk. Ewelina assumes the new position after serving as Director Corporate and Business Development since November 2019.

"We would like to thank Bryan for the outstanding contribution he has made to TME Pharma during his time as CFO, in particular the expertise he provided by improving the profile of the company and bringing it to the attention of new investors in the US and Europe. Bryan has prepared the company to enter global exchanges as potential hosts for our shares, and by driving the introduction of new capital structures, including share consolidation and a preferred share class, has created an attractive balance sheet for long-term institutional investors. With that job done, we continue to reach out to the investor communities while evaluating and reacting to challenging market conditions," said Aram Mangasarian, CEO of TME Pharma. "We wish Bryan all the best in his future endeavors, and we thank him for his help in ensuring a smooth transition with Heike, Karen and Ewelina. Ewelina has been heavily involved in the business development and financing activities of the company since she joined us in 2018 and she has the knowledge, capabilities and passion to help TME Pharma communicate on its outstanding clinical data. Heike and Karen have been with the firm since early 2000 and have an exceptional grasp of financial reporting, financial planning as well as legal and contractual commitments. TME remains well equipped to continue attracting investors and strategic partners."

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  117   |   |   

Schreibe Deinen Kommentar

Disclaimer

TME Pharma Announces the Resignation of Its Chief Financial Officer Bryan Jennings Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company's …

Nachrichten des Autors

208 Leser
192 Leser
180 Leser
172 Leser
160 Leser
864 Leser
812 Leser
748 Leser
484 Leser
476 Leser
3232 Leser
2096 Leser
1900 Leser
1604 Leser
1160 Leser
7528 Leser
3232 Leser
3049 Leser
2934 Leser
2489 Leser